TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10228251

Group type: EXPERIMENTAL
Intervention: Routine sedation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sedation as needed
Number of subjects: 70
Study: 8558641

Group type: EXPERIMENTAL
Intervention: Intravesical plus intradermal BCG
Number of subjects: 154

Group type: COMPARATOR
Intervention: Intravesical BCG only
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Fever after BCG instillation
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Positive purified protein derivative skin test before treatment
Number of subjects: 154
Study: 1678761

Group type: EXPERIMENTAL
Intervention: Triple dose cefuroxime
Number of subjects: 415

Group type: COMPARATOR
Intervention: Single dose cefuroxime
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Triple dose cefuroxime plus metronidazole
Number of subjects: 415

Group type: COMPARATOR
Intervention: Single dose cefuroxime plus metronidazole
Number of subjects: 415
Study: 6138595

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 17

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 17
Study: 3908104

Group type: EXPERIMENTAL
Intervention: Timolol treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 28649755

Group type: EXPERIMENTAL
Intervention: Preoperative geriatric assessment followed by tailored intervention
Number of subjects: 122

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 122
Study: 27678079

Group type: EXPERIMENTAL
Intervention: Telephone coaching intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual diabetes care (control)
Number of subjects: 0
Study: 25831700

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Dabigatran (220 mg)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 121
Study: 22503941

Group type: EXPERIMENTAL
Intervention: Nasal pillows
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Nasal masks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Oronasal masks
Number of subjects: 55
Study: 20479419

Group type: EXPERIMENTAL
Intervention: Doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² every 3 weeks for four cycles followed by paclitaxel 175 mg/m² every 3 weeks for four cycles (AC->P)
Number of subjects: 1801

Group type: COMPARATOR
Intervention: Doxorubicin 50 mg/m² plus paclitaxel 200 mg/m² every 3 weeks for four cycles followed by paclitaxel 80 mg/m² weekly for 12 weeks (AP-WP)
Number of subjects: 1801
Study: 18705538

Group type: EXPERIMENTAL
Intervention: 600 mg/day oral magnesium citrate supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study: 15625087

Group type: EXPERIMENTAL
Intervention: Hypocretin-deficient narcoleptic men
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study: 12872794

Group type: EXPERIMENTAL
Intervention: 2% ibopamine eye drops
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 30
Study: 10496658

Group type: EXPERIMENTAL
Intervention: Ipamorelin at 4.21 nmol/kg over 15 minutes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ipamorelin at 14.02 nmol/kg over 15 minutes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ipamorelin at 42.13 nmol/kg over 15 minutes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ipamorelin at 84.27 nmol/kg over 15 minutes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ipamorelin at 140.45 nmol/kg over 15 minutes
Number of subjects: 40
Study: 8959632

Group type: EXPERIMENTAL
Intervention: Calcium mupirocin 2% (Bactroban nasal) applied twice daily for 5 consecutive days every 4 weeks
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo ointment applied twice daily for 5 consecutive days every 4 weeks
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Calcium mupirocin 2%
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 267
Study: 2036493

Group type: EXPERIMENTAL
Intervention: Playing SwedeBall at 0 degrees C
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Playing SwedeBall at -7 degrees C
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pedaling at -10 degrees C
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pedaling at 8 degrees C
Number of subjects: 44

Group type: COMPARATOR
Intervention: Pedaling at 26 degrees C
Number of subjects: 44
Study: 6122004

Group type: EXPERIMENTAL
Intervention: Opsonisation of T lymphocytes with 1 mg of the murine monoclonal antibody OKT3 before infusion
Number of subjects: 17

Group type: COMPARATOR
Intervention: Prophylactic methotrexate
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Opsonisation of T lymphocytes
Number of subjects: 17
Study: 31012850

Group type: EXPERIMENTAL
Intervention: Guidewire tracking in collateral channels during retrograde PCI
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Prediction score model for CC GW crossing success
Number of subjects: 886
Study: 30940870

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 22
Study: 28836458

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 414

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 414
Study: 27283723

Group type: EXPERIMENTAL
Intervention: Intra-space injection of dexamethasone (4 mg) with 2% lignocaine and 1:200,000 epinephrine (SS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intramuscular injection of dexamethasone (4 mg) with standard inferior alveolar nerve block (CS)
Number of subjects: 30
Study: 25248371

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exclusive oral-feeding supply
Number of subjects: 0
Study: 22507090

Group type: EXPERIMENTAL
Intervention: Colonoscopy with abdominal corset
Number of subjects: 216

Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 216
Study: 20234140

Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis (6 x 2.0 x 10(9) CFU/kg/day, 12 billion CFU/kg/day)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis
Number of subjects: 183
Study: 17279004

Group type: EXPERIMENTAL
Intervention: Chewing gum (5 pieces per day)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Standard oral care
Number of subjects: 145
Study: 16218173

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) 400/100 mg twice daily
Number of subjects: 339

Group type: COMPARATOR
Intervention: Saquinavir/ritonavir (SAQ/r) 1000/100 mg twice daily
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Saquinavir/ritonavir (SAQ/r)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) and Saquinavir/ritonavir (SAQ/r)
Number of subjects: 339
Study: 11218421

Group type: EXPERIMENTAL
Intervention: Personal exposure to formaldehyde
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Personal exposure to acetaldehyde
Number of subjects: 15

Group type: COMPARATOR
Intervention: Indoor residential concentrations of formaldehyde
Number of subjects: 15

Group type: COMPARATOR
Intervention: Indoor residential concentrations of acetaldehyde
Number of subjects: 15

Group type: COMPARATOR
Intervention: Ambient air concentrations of formaldehyde and acetaldehyde
Number of subjects: 15

Group type: COMPARATOR
Intervention: Workplace concentrations of formaldehyde and acetaldehyde
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Correlation between personal exposures and indoor residential concentrations
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Time-weighted exposure model
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Correlation between formaldehyde and acetaldehyde in outdoor microenvironments
Number of subjects: 15
Study: 9773732

Group type: EXPERIMENTAL
Intervention: BCG vaccination (0.1 ml, 100 microg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (0.1 ml saline)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control
Number of subjects: 26
Study: 8011827

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics administration
Number of subjects: 0
Study: 3072016

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Morphine 10 mg alone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 40
Study: 30511963

Group type: EXPERIMENTAL
Intervention: High-dose live attenuated VZV vaccine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Delayed-start group (control)
Number of subjects: 44
Study: 28384010

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 76
Study: 25574795

Group type: EXPERIMENTAL
Intervention: Progesterone for the Treatment of Traumatic Brain Injury
Number of subjects: 85
Study: 23875707

Group type: EXPERIMENTAL
Intervention: Genotypic tropism testing (GTT) using geno2pheno algorithm
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Enhanced-sensitivity Trofile assay (ESTA)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Ultradeep sequencing (UDS)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Concordant non-R5 results by UDS and ESTA
Number of subjects: 304
Study: 21957032

Group type: EXPERIMENTAL
Intervention: High-protein/low-glycaemic index (HP/LGI) diet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-protein/low-glycaemic index (LP/LGI) diet
Number of subjects: 24
Study: 19632963

Group type: EXPERIMENTAL
Intervention: F‐Scan insole plantar pressure system
Number of subjects: 15
Study: 17910651

Group type: EXPERIMENTAL
Intervention: Early steroid withdrawal (decreasing steroid doses stopping at day 7 post-transplant)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Early steroid withdrawal
Number of subjects: 23

Group type: COMPARATOR
Intervention: Steroid-based control group (CsA, AZT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Steroid-based control group
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23
Study: 15142000

Group type: EXPERIMENTAL
Intervention: Supervised resistance training (SUP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Unsupervised resistance training (UNSUP)
Number of subjects: 42
Study: 11549952

Group type: EXPERIMENTAL
Intervention: Moist Exposed Burn Ointment (MEBO)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Conventional management (C)
Number of subjects: 115
Study: 9513957

Group type: EXPERIMENTAL
Intervention: Paravertebral blockade (steroid + local anaesthetic)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conservative treatment (spine-decompressing position, traction, therapeutic exercises)
Number of subjects: 103
Study: 8400091

Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms/kg)
Number of subjects: 43
Study: 3020754

Group type: EXPERIMENTAL
Intervention: CDDP + DVA
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: CDDP + VP16
Number of subjects: 116

Group type: COMPARATOR
Intervention: DXR + CTX
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Toxicity
Number of subjects: 116
Study: 31030774

Group type: EXPERIMENTAL
Intervention: Hydrophobic POD F GF IOL
Number of subjects: 25
Study: 29773818

Group type: EXPERIMENTAL
Intervention: Anti-malarial compounds in EIA
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: pIC50 for 11 different compounds in EIA
Number of subjects: 44
Study: 26415743

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention (PI)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 113
Study: 23949133

Group type: EXPERIMENTAL
Intervention: Standard right-thread interference screw for femoral graft fixation
Number of subjects: 107
Study: 22234626

Group type: EXPERIMENTAL
Intervention: Hysterectomy (HT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: No hysterectomy (HT)
Number of subjects: 61
Study: 21211323

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) administered for 1 - 3 cycles before radical hysterectomy and lymphadenectomy.
Number of subjects: 139

Group type: COMPARATOR
Intervention: Director operation (DOR) without prior chemotherapy, radical hysterectomy performed directly after diagnosis.
Number of subjects: 139
Study: 18394771

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (FD; 1100 ppmF) + 3 applications of acidulated phosphate fluoride (APF; 12,300 ppmF)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (FD; 1100 ppmF) + 4 applications of acidulated phosphate fluoride (APF; 12,300 ppmF)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Fluoride dentifrice (FD; 1100 ppmF)
Number of subjects: 5
Study: 16009171

Group type: EXPERIMENTAL
Intervention: Raloxifene 180 mg/day orally for three cycles of 28 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo tablets (3 tablets/day orally)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 14563546

Group type: EXPERIMENTAL
Intervention: Slow-release oral morphine (SROM)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 14
Study: 10392680

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8658378

Group type: EXPERIMENTAL
Intervention: Substance P (5-100 pmol/min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Adenosine (5-50 micrograms/kg/min)
Number of subjects: 6
Study: 8316387

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 7
Study: 2878597

Group type: EXPERIMENTAL
Intervention: Bevantolol 400 mg
Number of subjects: 229

Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 229
Study: 31759333

Group type: EXPERIMENTAL
Intervention: Single ketamine infusion
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Repeated ketamine infusions (six infusions thrice-weekly over 2 weeks)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Maintenance infusions (four further infusions once-weekly)
Number of subjects: 37
Study: 30175606

Group type: COMPARATOR
Intervention: Corticosteroid
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (low molecular weight)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (high molecular weight)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (third administration)
Number of subjects: 37
Study: 27085606

Group type: EXPERIMENTAL
Intervention: 7 mg nicotine patch
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Resting state connectivity analysis
Number of subjects: 37
Study: 24173681

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 45
Study: 21182551

Group type: EXPERIMENTAL
Intervention: Active gum (2 mg or 4 mg)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Active gum (compliant use ≥9 pieces/day)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Active gum (non-compliant use <9 pieces/day)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Active treatment (2 mg or 4 mg)
Number of subjects: 103
Study: 19403553

Group type: EXPERIMENTAL
Intervention: Custom-made semi-rigid insole
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ready-made simple soft insole
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the comparison group with different insoles)
Number of subjects: 42
Study: 17446413

Group type: EXPERIMENTAL
Intervention: Intralipid (0.8 ml x m(‐2) x min(‐1)) and heparin (1,000 U/h)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (0.8 ml x m(‐2) x min(‐1)) and heparin (1,000 U/h)
Number of subjects: 18
Study: 15213282

Group type: EXPERIMENTAL
Intervention: Intradialytic parenteral nutrition (IDPN)
Number of subjects: 7

Group type: COMPARATOR
Intervention: No IDPN (Control)
Number of subjects: 7
Study: 11245710

Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9143758

Group type: EXPERIMENTAL
Intervention: High-compliance balloons
Number of subjects: 800

Group type: COMPARATOR
Intervention: Low-compliance balloons
Number of subjects: 800
Study: 8130921

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches (delivering 15 mg over 16 hours) with low-intensity support
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo with low-intensity support
Number of subjects: 248
Study: 3654238

Group type: EXPERIMENTAL
Intervention: UAB program (special intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 31650529

Group type: EXPERIMENTAL
Intervention: Active iliopsoas plane block (5 mL lidocaine 18 mg/mL with epinephrine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham iliopsoas plane block (saline)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active iliopsoas plane block
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham iliopsoas plane block
Number of subjects: 20
Study: 29313751

Group type: EXPERIMENTAL
Intervention: 2-dose-ZW (28 g)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 1-dose-ZW (14 g)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 28088231

Group type: EXPERIMENTAL
Intervention: Gabapentin (maximum of 1800 mg/day for 5 weeks)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 25325608

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Diabetes and support education (DSE)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Overall population (both ILI and DSE)
Number of subjects: 264
Study: 24289111

Group type: EXPERIMENTAL
Intervention: Teamplay parenting intervention
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 20663456

Group type: EXPERIMENTAL
Intervention: Palm blood glucose testing (PBGT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional fingertip blood glucose testing (FBGT)
Number of subjects: 0
Study: 17632023

Group type: EXPERIMENTAL
Intervention: Tulobuterol (2mg/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Salmeterol (50 microg, twice daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Tulobuterol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Salmeterol
Number of subjects: 11
Study: 16893984

Group type: EXPERIMENTAL
Intervention: 10 microg PS antigen
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: 50 microg PS vaccinating dose
Number of subjects: 281

Group type: COMPARATOR
Intervention: Baseline samples
Number of subjects: 281

Group type: COMPARATOR
Intervention: Days 2 to 3
Number of subjects: 281
Study: 12925477

Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 72

Group type: COMPARATOR
Intervention: Classic LMA
Number of subjects: 72
Study: 10773644

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 9009369

Group type: EXPERIMENTAL
Intervention: 0.04% mitomycin C eye drops, four times daily for two weeks or longer after surgery
Number of subjects: 66

Group type: COMPARATOR
Intervention: Surgery only (no mitomycin C)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 0.04% mitomycin C eye drops
Number of subjects: 66
Study: 2058822

Group type: EXPERIMENTAL
Intervention: Preoperative autologous deposit
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Preoperative hemodilution
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Intra- and postoperative autotransfusion
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 12265805

Group type: EXPERIMENTAL
Intervention: Nylon T IUD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Copper T 200
Number of subjects: 0
Study: 30819458

Group type: EXPERIMENTAL
Intervention: Incredible Years Teacher Classroom Management program (IY TCM)
Number of subjects: 0
Study: 28893755

Group type: EXPERIMENTAL
Intervention: Web-based menu planning intervention with training and follow-up support
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 54
Study: 25642812

Group type: EXPERIMENTAL
Intervention: Bromfenac sodium hydrate (NSAID)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Flavin adenine dinucleotide sodium (Control)
Number of subjects: 28
Study: 25189175

Group type: EXPERIMENTAL
Intervention: Hypertonic sodium lactate solution (HSL) - 5 ml/kg/BW in 15 minutes followed by 1 ml/kg/BW/h for 12 hours
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ringer lactate (RL) - 20 ml/kg/BW in 15 minutes followed by decreasing doses of 10, 7, 5, and 3 ml/kg BW/h for 12 hours
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hypertonic sodium lactate solution (HSL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ringer lactate (RL)
Number of subjects: 50
Study: 22005922

Group type: EXPERIMENTAL
Intervention: Suction catheter aspiration
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Forceps biopsy
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Combination of both techniques
Number of subjects: 272
Study: 20141250

Group type: EXPERIMENTAL
Intervention: Attention training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 17555932

Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Peak gradient 80 mm Hg or greater
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Aortic valve area less than or equal to 0.75 cm(2)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Large left ventricular outflow tract dimension
Number of subjects: 208

Group type: COMPARATOR
Intervention: Normal left ventricular outflow tract dimension
Number of subjects: 208